Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Erimos Pharmaceuticals
With
University of Maryland, Baltimore County
Planned Parenthood Delaware (Wilmington, DE)
This was an open-label, pilot Phase I/II dose evaluation and pharmacokinetic evaluation study to compare the safety and efficacy of terameprocol (45mg or 90mg/application)administered once per week for 3 weeks to the cervix uteri in patients with biopsy-proven CIN. Patients who met eligibility criteria visited the clinic weekly for terameprocol application. Patients kept a daily diary card record of genitourinary symptoms.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
18 years of age or older
Negative pregnancy test
Biopsy confirmed CIN 1, 2, or 3
You may not be if
Pregnancy or breast feeding
Clareo Health | A Pilot Study of EM-1421 for the Treatment of Cervical Intraepithelial Neoplasia
